Leap Therapeutics, Inc. announced it has entered into a Securities Purchase Agreement with certain institutional investors to issue 12,660,993 shares at a issue price of $2.82 for gross proceeds of $35,704,000.26 and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock issuable upon exercise of the pre-funded warrants for gross proceeds of $4,295,999.74, resulting aggregate gross proceeds of $40,000,000 on April 10, 2024. The transaction included participation from existing investor Samsara BioCapital LLC and new investors Gilead Sciences, Inc., 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs Capital. The transaction is expected to close on April 15, 2024, subject to satisfaction of customary closing conditions.